Validation of the European Prognostic Index for younger adult patients with acute myeloid leukaemia in first relapse

Francis Giles*, Srdan Verstovsek, Guillermo Garcia-Manero, Deborah Thomas, Farhad Ravandi, William Wierda, Alessandra Ferrajoli, Steve Kornblau, Elias Jabbour, Jianqin Shan, Susan O'Brien, Maher Albitar, Hagop Kantarjian

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

18 Scopus citations

Abstract

In order to validate the European Prognostic Index (EPI) for patients ≤60 years with acute myeloid leukaemia in first relapse, a cohort of 599 such patients, treated between 1980 and 2004 at the MD Anderson Cancer Center, were assessed using this prognostic index. Three risk groups were defined: favourable, 76 patients (13%) [Overall survival (OS), 64% at 1 year, 22% at 5 years]; intermediate, 137 patients (23%) (OS, 38% at 1 year, 12% at 5 years); and poor, 386 patients (64%) (OS, 17% at 1 year 6% at 5 years). The EPI is reproducible and useful.

Original languageEnglish (US)
Pages (from-to)58-60
Number of pages3
JournalBritish Journal of Haematology
Volume134
Issue number1
DOIs
StatePublished - Jul 2006

Keywords

  • Acute myeloid leukaemia
  • First relapse
  • Prognosis

ASJC Scopus subject areas

  • Hematology

Fingerprint Dive into the research topics of 'Validation of the European Prognostic Index for younger adult patients with acute myeloid leukaemia in first relapse'. Together they form a unique fingerprint.

Cite this